882 related articles for article (PubMed ID: 16083515)
1. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
2. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterases: roles in the brain during health and disease.
Ballard CG; Greig NH; Guillozet-Bongaarts AL; Enz A; Darvesh S
Curr Alzheimer Res; 2005 Jul; 2(3):307-18. PubMed ID: 15974896
[TBL] [Abstract][Full Text] [Related]
4. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
5. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
8. Acetylcholinesterase and its inhibition in Alzheimer disease.
Lane RM; Kivipelto M; Greig NH
Clin Neuropharmacol; 2004; 27(3):141-9. PubMed ID: 15190239
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
12. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM
J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402
[TBL] [Abstract][Full Text] [Related]
13. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
14. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
Poirier J
Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
[TBL] [Abstract][Full Text] [Related]
15. Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value.
Lane RM; Darreh-Shori T
J Alzheimers Dis; 2015; 44(4):1039-62. PubMed ID: 25408210
[TBL] [Abstract][Full Text] [Related]
16. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
18. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
19. Mice heterozygous for AChE are more sensitive to AChE inhibitors but do not respond to BuChE inhibition.
Mohr F; Zimmermann M; Klein J
Neuropharmacology; 2013 Apr; 67():37-45. PubMed ID: 23147415
[TBL] [Abstract][Full Text] [Related]
20. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J
Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]